Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results
Hussain, SA Maroto, P Climent, MA Bianchini, D Jones, RH Lin, CC Wang, SS Crossley, K Schlieker, L
Hussain, SA
Maroto, P
Climent, MA
Bianchini, D
Jones, RH
Lin, CC
Wang, SS
Crossley, K
Schlieker, L
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Hussain SA, Maroto P, Climent M�, Bianchini D, Jones RH, Lin C-C, et al. Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results. J Clin Oncol. 2019;37(15_suppl):5030-.